Intriguingly, both RAC1 activity and CDC42 activity have been associated with therapeutic resistance in different cancer types, including enzalutamide resistance in CRPC, and RAC/CDC42 inhibition has been suggested as a potential approach to overcome resistance to PI3K–AKT–mTOR-targeted treatments [294,295,296,297,298]. The gene discussed is PIK3CD; the disease is cancer.